New England Council member Boston Scientific recently announced it is buying Symetis, a Switzerland-based company that makes heart valve systems, for $435 million.
Symetis makes heart valve systems sold outside the U.S. to treat high-risk patients with severe cardiac valve conditions in minimally invasive procedures. By acquiring Symetis, Boston Scientific will expand the company’s treatments for patients with aortic valvular heart diseases in New England and worldwide.
“The steps we are taking reflect our commitment to being a leader in TAVI and structural heart technologies now and over the long-term, as we broaden our portfolio and pipeline to address the needs of our global health care providers and their patients,” said Boston Scientific Global Medical Officer Dr. Ian Meredith.
The New England Council congratulates Boston Scientific on the addition of Symetis and the company’s continued leadership and innovation in treating aortic valve conditions. Read more in Worcester Business Journal and Mass Device.
Recently from the Blog
NEC Announces COVID In-Person Event Policy; Plans Return to In-Person Programming in 2022